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Abstract
 
Using a bioassay consisting of the proliferation of a murine B cell line, a cDNA of a gene
whose product supports the growth of that cell line was isolated from a thymic stromal cell line.
This factor, termed thymic stromal lymphopoietin (TSLP), is a protein of 140 amino acids.
The gene encoding TSLP was mapped to murine chromosome 18. Purified recombinant TSLP
supported the growth of pre-B cell colonies in vitro, but had no myelopoietic activity. TSLP
had comitogenic activity for fetal thymocytes, but was not as potent as interleukin 7 in lobe
submersion cultures. Injection of TSLP into neonatal mice induced the expansion of
 
B220
 
1
 
BP-1
 
1
 
 pre-B cells.
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Introduction
 
The development of functional B and T lymphocytes from
their immature precursor cells has been extensively studied
in the last several years. The process of expansion and mat-
uration is regulated by soluble and membrane-bound
ligands that have distinct but overlapping roles (1, 2). De-
spite a long list of cytokines that influence the proliferation
and differentiation of B and T cell precursors, in vitro sys-
tems have been unable to faithfully recapitulate all of the
developmental steps observed in vivo, which supports the
notion that additional growth factors may exist.
One approach to identification of cytokines that stimu-
late the process of hematolymphoid development has been
to derive stromal cell lines from various tissues and assess
their ability to sustain active lymphopoiesis in vitro (3–5).
We reported previously on the derivation and characteriza-
tion of a phenotypically unique thymic stromal cell clone,
Z210R.1, that when cocultured with lymphoid precursors
from murine fetal liver resulted in vigorous B cell develop-
ment (6). A nonadherent B lymphoid cell line (NAG8/7)
was derived from this culture system and this cell line was
shown to be dependent on stromal cell–conditioned me-
dium for survival and expansion (6). Using the proliferative
response of the NAG8/7 cell line as a bioassay, we have
isolated a novel cDNA from a Z210R.1 expression library
by direct expression screening. The expressed protein,
 
termed thymic stromal lymphopoietin (TSLP),
 
1
 
 shares an
overlapping but distinct biological profile with IL-7, and
utilizes components of the IL-7 receptor system (see Park
et al. in this issue [7]).
 
Materials and Methods
 
TSLP Assay.
 
TSLP bioactivity was assessed in the NAG8/7
proliferation assay as described (6). In brief, NAG8/7 cells were
seeded into 96-well flat-bottomed tissue culture wells (Corning)
 
at a density of 2 
 
3
 
 10
 
4
 
 cells/well in RPMI 1640 (GIBCO BRL),
10% fetal bovine serum (Hyclone), 100 U/ml penicillin, 100 mg/
 
ml streptomycin, 50 
 
m
 
M 2-ME, and 2 mM 
 
l
 
-glutamine (GIBCO
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BRL). Cultures were incubated for 48 h at 37
 
8
 
C in a humidified
atmosphere containing 5% CO
 
2
 
. Proliferation was assessed by 
 
3
 
H-
TdR incorporation (1 
 
m
 
Ci/well was added for the last 16 h of
culture).
 
cDNA Cloning.
 
RNA was isolated from Z210R.1 cells,
oligo-dT–primed cDNA was synthesized and cloned into the
pDC406 vector, pools of clones were generated, and transfections
into CV-1/EBNA cells were performed, all as described (8). Su-
pernatants from the CV-1/EBNA cells were harvested 3 d after
transfection and assayed directly for NAG8/7 cell proliferative ac-
tivity as described above. After finding a positive pool, a single
clone was subsequently isolated from it as described (8). The in-
sert from this clone, clone 17, was then used to screen an oligo-
dT–primed Z210R.1 cDNA library made in
 
 
 
l
 
gt10, from which
two other clones (2-1 and 1A) were isolated. The extent of each
clone with reference to Fig. 1 is: clone 17, nucleotides 7–750;
clone 2-1, nucleotides 1–750; clone 1A, nucleotides 27–1125.
 
RNA Hybridization.
 
PolyA
 
1
 
 RNA (5 
 
m
 
g) was run on aga-
rose gels, transferred to a nylon membrane, and hybridized to a
 
32
 
P-labeled antisense riboprobe derived from the entire coding
region and 
 
z
 
300 bases of 3
 
9
 
 untranslated region as described (8).
The final wash of the filters was for 30 min at 63
 
8
 
C in 0.2
 
3 
 
SSC.
 
Reverse Transcription and PCR Analysis.
 
RNA was extracted
from freshly isolated mouse tissue according to the method of Ca-
thala et al. (9). Contaminating genomic DNA was removed from
RNA samples by treatment with DNAase I (Boehringer) as per
the manufacturer’s instructions. Samples were ethanol precipi-
tated and resuspended in water before reverse transcription (RT)
with SuperScript II (GIBCO BRL) and oligo-dT primers as per
the manufacturer’s instructions. Mock-transcribed samples lack-
ing reverse transcriptase were included in each sample. Reaction
products were normalized for cDNA content with the hypoxan-
thine phosphoribosyltransferase (HPRT) competitor of the poly-
competitor construct PQRS provided by R.M. Locksley (Uni-
versity of California at San Francisco, San Francisco, CA;
reference 10). Titrated amounts of polycompetitor vector were
added to 1 ml aliquots of RT reaction products and PCR ampli-
fied with HPRT primers as described previously (10). Densitom-
etry of ethidium bromide–stained PCR products was performed
to calculate the equivalence of PQRS vector for each cDNA
preparation. Volumes of tissue cDNA containing equivalent
amounts of HPRT activity were then amplified to detect TSLP
mRNA.
Primers used for TSLP PCR were: (a) 5
 
9
 
-TGCAAGTAC-
TAGTACGGATGGGGC-3
 
9
 
 from the 5
 
9
 
 end of the coding re-
gion of the TSLP gene; and (b) 5
 
9
 
-GGACTTCTTGTGC-
CATTTCCTGAG-3
 
9
 
 from the 3
 
9
 
 end of the coding region of
the TSLP gene. This primer pair yields the expected 323-bp
product. 0.5–2.0-pg equivalents of HPRT were amplified for 35
or 40 cycles (Omnigene thermocycler) in a 50-
 
m
 
l reaction con-
taining 1.5 mM MgCl
 
2
 
, 400 nM sense and antisense primers, 200
 
m
 
M dNTP, and 0.25 
 
m
 
l of Taq polymerase (GIBCO BRL). Cy-
cling conditions for all TSLP amplifications were 30 s at 94
 
8
 
C,
followed by 30 s at 62
 
8
 
C and a final extension of 10 min at 72
 
8
 
C.
 
Chromosomal Mapping.
 
Interspecific backcross progeny were
generated by mating (C57BL/6J 
 
3
 
 
 
Mus. spretus
 
) F1 females and
C57BL/6J males as described (11). A total of 205 N2 mice were
used to map the 
 
Tslp
 
 locus. DNA isolation, restriction enzyme
digestion, agarose gel electrophoresis, Southern blot transfer, and
hybridization were performed as described (12). All blots were
prepared with Hybond-N1 nylon membrane (Amersham Phar-
macia Biotech). The probe, an 
 
z
 
790-bp fragment of mouse
cDNA, was labeled with [
 
a
 
-
 
32
 
P]dCTP using a random primed la-
 
beling kit (Stratagene); washing was done to a final stringency of
1.0
 
3
 
 SSCP, 0.1% SDS, 65
 
8
 
C. A fragment of 8.2 kb was detected
in KpnI-digested C57BL6/J DNA and a fragment of 14.5 kb in
KpnI-digested 
 
M
 
.
 
 spretus
 
 DNA. A description of the probes and
RFLPs for the loci linked to the gene for TSLP 
 
(
 
Tslp
 
), including
desmoglein, 
 
adenomatosis polyposis coli
 
 (
 
Apc
 
), and fibroblast growth
factor 1, has been reported previously (13, 14). Recombination
distances were calculated as described using the computer pro-
gram SPRETUS MADNESS (15). Gene order was determined
by minimizing the number of recombination events required to
explain the allele distribution patterns.
 
Purification of CV-1/EBNA–expressed TSLP. 
 
Approximately
1 liter of CV-1/EBNA cell supernatant containing TSLP was di-
luted 1:4 with 20 mM Tris, pH 7.5 (buffer A), and applied to a
190 ml Q-Sepharose Fast Flow column (Amersham Pharmacia
Biotech) equilibrated with buffer A. The column was washed
with 500 ml buffer A and then eluted with a 1,000 ml linear gra-
dient of 0–300 mM NaCl in buffer A. TSLP-containing fractions
were identified by NAG8/7 bioassay. Active fractions from two
Q-Sepharose columns were concentrated to 
 
z
 
60 ml, adjusted to
pH 3.5 with 1 M citric acid, and applied to a 42 ml S-Sepharose
Fast Flow column (Amersham Pharmacia Biotech) equilibrated
with 20 mM citric acid, 100 mM sodium chloride, pH 3.5 (buffer
B). The column was washed with 60 ml buffer B and then eluted
with a 500 ml linear gradient of buffer B to 50 mM trisodium ci-
trate, 50 mM sodium chloride, pH 6.5. Active fractions were
identified by NAG8/7 bioassay, concentrated to 4 ml using a
YM10 ultrafiltration membrane (Amicon) and chromatographed
on a 2.6 
 
3
 
 90 cm Sephacryl S-100 HR column (Amersham
Pharmacia Biotech) equilibrated with 20 mM Tris, 150 mM, pH
7.5. Active fractions from two Sephacryl S-100 HR columns
were pooled, adjusted to pH 2 with 10% TFA in water, and puri-
fied by reversed-phase (RP)-HPLC on a 0.46 
 
3
 
 22 cm RP300
column (Applied Biosystems) using a gradient of acetonitrile in
0.1% TFA. The gradient was 0–25% acetonitrile in 10 min fol-
lowed by 25–50% acetonitrile in 50 min TSLP eluted at 
 
z
 
39%
acetonitrile.
 
Yeast Expression of TSLP.
 
A cDNA fragment encoding the
gene for TSLP was generated using the PCR and subcloned into
the
 
 
 
Kluyveromyces lactis
 
 
 
expression vector, YIpK. This vector is
composed of the yeast integrating vector, YIp5 (16), with added
sequences that comprise the LAC4 promoter of 
 
K. lactis
 
 (17, 18)
and the secretion leader from the
 
 
 
a
 
-factor gene of 
 
Saccharomyces cer-
evisiae
 
 (19) included between the EcoRI and BamHI sites of Yip5.
The oligonucleotide sequences of the primers used to generate
the cDNA fragment encoding TSLP are as follows: 5
 
9
 
 primer, 5
 
9
 
-
ATATGGTACCTTTGGATAAAAGATACAACTTTTCTA-
ACTGCAACTTG-3
 
9
 
, and 3
 
9
 
 primer, 5
 
9
 
-ATATCCATGGT-
TATTCTGGAGATTGCATGAAGGAATA-3
 
9
 
. The fragment
allows the fusion of the TSLP cDNA in frame to the 
 
a
 
-factor
leader sequence at an Asp718 site.
The vector was integrated into the genome of 
 
K
 
.
 
 lactis
 
 strain
MW98 by homologous recombination into the LAC4 promoter
region. For expression of the recombinant TSLP, yeast cells were
grown for 48 h in a medium consisting of 1% yeast extract
(Difco), 2% peptone (Difco), and 2% galactose (Sigma-Aldrich).
Cells were then removed by centrifugation and the medium was
filtered through a 0.45-
 
m
 
 cellulose acetate filter. The recombinant
protein was recovered from the supernatant; alternatively, the
sterile yeast supernatant was assayed directly for TSLP biological
activity.
 
Purification of Yeast-expressed TSLP.
 
6.5 L of yeast broth con-
taining TSLP was diluted 1:2 with 20 mM citric acid, 50 mM so- 
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dium chloride, pH 3.5, adjusted to pH 3.5 with 1 M citric acid,
and applied to a 470-ml S-Sepharose column (Amersham Phar-
macia Biotech) equilibrated with the dilution buffer. The column
was washed with buffer until the absorbance at 280 nm returned
to baseline, and TSLP was then eluted with 50 mM Hepes, 100
mM NaCl, pH 7. Fractions containing TSLP were identified by
SDS-PAGE, pooled, diluted 1:2 in buffer A, adjusted to pH 7.5
with 1 M Tris base, and applied to a 182-ml Q-Sepharose Fast
Flow column (Amersham Pharmacia Biotech) equilibrated with
buffer A. The column was washed with buffer A until the absor-
bance at 280 nm returned to baseline and then eluted with a
1,200-ml linear gradient of 0–300 mM NaCl in buffer A. TSLP-
containing fractions were identified by NAG8/7 bioassay and
SDS-PAGE, concentrated to 4.5 ml using Centriprep-10 con-
centrators (Amicon), and chromatographed on a HiLoad 26/60
Superdex 75 column (Amersham Pharmacia Biotech) equilibrated
with PBS. TSLP-containing fractions were identified by NAG8/7
bioassay and SDS-PAGE. SDS-PAGE analysis showed 24- and
30-kD major forms of TSLP that were partially resolved by the
last gel filtration chromatography step. A 21-kD minor species of
TSLP as well as hyperglycosylated forms of TSLP were also de-
tected.
 
Peptide Mapping and Disulfide Group Determination.
 
TSLP (6
mg) purified from CV-1/EBNA cells was digested at 37
 
8
 
C for 16 h
with 0.4 
 
m
 
g modified trypsin (Promega) in 45 
 
m
 
l of 0.1 M Tris,
pH 8. The digest was diluted 1:2 with 0.1% TFA, adjusted to pH
2 with 10% TFA, and peptides were separated by RP-HPLC on a
0.21 
 
3
 
 15 cm Vydac C18 column (Separations Group) with a
linear gradient of acetonitrile (0–60% in 90 min) in 0.1% TFA.
The elution was monitored at 214 nm, and peptides were col-
lected manually and sequenced on an HP G1000A protein se-
quencer (Hewlett Packard). An equivalent digest was also ana-
lyzed by RP-HPLC/mass spectrometry (20).
 
Colony Assays.
 
Bone marrow colony assays to detect pre-B
colony-forming cells (CFU–pre-B) were initiated by a modifica-
tion of the method as described (21) in which agarose (SeaPlaque;
FMC Corp.) was substituted for agar. Granulocyte–macrophage
CFU were cultured as described (22). All growth factors used to
stimulate colony growth (IL-7, TSLP, GM-CSF, IL-3, CSF-1,
and G-CSF) were produced at Immunex Corporation as de-
scribed previously (23) and used at a plateau concentration of 20
ng/ml. In some experiments, cultures were initiated in methyl-
cellulose cultures (StemCell Technologies Inc.) to allow isolation
of individual colonies for phenotypic analysis. Cultures were in-
cubated for 7 d at 37
 
8
 
C in a fully humidified atmosphere of 5%
O
 
2
 
, 5% CO
 
2
 
, and 90% N
 
2
 
, and aggregates of 
 
.
 
40 cells were
scored as a colony using an inverted microscope.
Individual colonies in methylcellulose cultures were removed
with a finely drawn Pasteur pipet. Colonies were pooled, washed
in PBS, and stained with fluorochrome-labeled Abs recognizing
Thy-1, B220, MAC-1, or IgM (BD PharMingen). Samples were
analyzed on a FACStar
 
PLUS™
 
 flow cytometer (Becton Dickinson)
with a minimum of 5,000 events collected per group.
 
Thymocyte Assays.
 
CD4
 
2
 
CD8
 
2
 
 thymocytes were purified
from adult thymocytes from 10–12-wk-old female C57BL/6J
mice (The Jackson Laboratory) by incubation with anti-CD4 and
anti-CD8 mAbs and rabbit complement as described (24). Adult
CD4
 
2
 
CD8
 
2
 
 thymocytes were cultured in 96-well flat-bottomed
plates (Costar) at a density of 5 
 
3
 
 10
 
4
 
 cells per well in a volume of
0.2 ml of DMEM with 5% fetal bovine serum and 5 
 
3
 
 1025 M
2-ME. Cultures were incubated for 3 d and were pulsed with 1
mCi of 3H-TdR per well for the last 6 h of incubation. Alterna-
tively, thymic lobe submersion cultures were established by plac-
ing day 14 fetal thymic lobes in a 24-well plate (Costar) in 1 ml of
medium as described (24). IL-7 was added at a concentration of
50 ng/ml, stem cell factor (SCF) at a concentration of 100 ng/ml,
and purified TSLP at 50 ng/ml. Cultures were incubated for 7 d,
then cells were harvested and counted.
In Vivo Treatment of Mice with TSLP. Litters of newborn
C57BL/6 mice were derived by timed matings. Beginning at 7 d
of age, neonatal mice were injected once daily with 200 ng of
purified yeast-derived TSLP, 200 ng of human IL-7, or diluent
(10 mg/ml mouse serum albumin) in 0.05 ml intraperitoneally.
Injections continued for 10 d with the dose of cytokine being in-
creased twofold after 5 d. Mice were killed within 24 h of the last
injection, and spleen and bone marrow were harvested for anal-
ysis.
mAbs and Flow Cytometric Analysis. The following mAbs
were used for detection of B cell subpopulations. Fluorochrome-
or biotin-conjugated anti-B220, anti–heat-stable antigen (HSA),
and anti-CD43 were purchased from BD PharMingen. Biotin-
conjugated anti–BP-1 was provided by Dr. Max Cooper (Uni-
versity of Alabama, Birmingham, AL). Fluorescein- or Texas
red–conjugated goat anti-IgM (m chain specific) was purchased
from Southern Biotechnology Associates, Inc. FITC-conjugated
polyclonal goat anti-IgD (d chain specific) was provided by Dr.
Fred Finkelman (University of Cincinnati Medical Center, Cin-
cinnati, OH). Cyanin-conjugated anti-B220 was provided by Dr.
Tom Waldschmidt (University of Iowa, Iowa City, IA). For
four-color analysis of pre-B cell populations, bone marrow was
incubated initially with anti-FcgRII mAb (2.4G2) and normal rat
sera, followed by simultaneous addition of Abs specific for pre-B
cell markers or surface m or surface d as described previously (25).
Stained cells were analyzed on a FACStarPLUS™ (Becton Dickin-
son). Data were analyzed using Repromac (TrueFacts Software).
Results
Isolation of a cDNA Clone Encoding TSLP. To isolate
cDNA clones encoding the B lineage growth and differen-
tiation activity found in supernatants of the Z210R.1 cell
line, we chose to utilize an approach involving direct ex-
pression in mammalian cells (7, 26). A cDNA library was
generated in a mammalian expression vector, using mRNA
from the Z210R.1 cell line. Pools of cDNA clones were
transfected into CV-1/EBNA monkey kidney cells, and 3 d
later the supernatants of the transfected cells were assayed
for TSLP biological activity using the NAG8/7 responder
cell line. After screening 82,000 cDNA clones, a positive
pool was found. This pool was then broken down into suc-
cessively smaller subpools until a single cDNA clone en-
coding the proliferative activity was isolated. The insert
from this clone was then used as a probe to isolate further
TSLP clones from a lgt10 cDNA library made from the
Z210R.1 cells, in order to confirm the representative na-
ture of the original clone.
The TSLP clones isolated had a single open reading
frame of 140 amino acids, including a predicted 19–amino
acid signal peptide (Fig. 1 A). The mature 121–amino acid
protein contains 3 potential sites for N-linked carbohydrate
addition and 7 cysteine residues. This is shown schemati-
cally in Fig. 1 B. There is a formal possibility that the natu-
ral TSLP protein is larger, since no stop codons are present674 Murine TSLP
in the short 59 untranslated regions contained in our cDNA
clones (although if that is the case the additional NH2-ter-
minal amino acids would seem to be unnecessary for
proper secretion and biological activity of the molecule).
The initiating methionine codon contained in the existing
clones does lie within an acceptable version of the Kozak
consensus sequence. The 39 untranslated region is z700
nucleotides long.
Expression of TSLP mRNA in Murine Tissues and Cell
Lines. Northern blots revealed a single hybridizing species
of mRNA that migrated somewhat faster than 18S rRNA
(Fig. 2 A), consistent with the mRNA size of z1,150 nu-
cleotides (not counting polyA) estimated from the cDNA
clones. In addition to the Z210R.1 cells, several other stro-
mal cell lines expressed TSLP mRNA, as did the EL4 T
cell lymphoma, lymphoid organs (thymus, spleen, and
bone marrow), and kidney. The pre-B cell lymphoma
70Z/3 was negative, as were brain and liver.
Analysis of other tissues from normal mice by RT-PCR
again demonstrated TSLP expression in thymus, spleen,
bone marrow, and lung (Fig. 2 B, a). Over several experi-
ments, there was variable expression of TSLP detected in
lymph nodes by RT-PCR. Peyer’s patches, brain, liver,
heart, ileum, and skeletal muscle were negative for TSLP ex-
pression by this method. Increasing the number of cycles of
the PCR reaction from 35 to 40 allowed detection of a band
of appropriate size in many of the tissues tested (Fig. 2 B, b).
Chromosomal Localization of the TSLP Gene. Tslp was
mapped to mouse chromosome 18 by analysis of DNA
from interspecific backcrosses between C57BL/6J and M.
Figure 1. The cDNA and predicted amino acid sequence of murine
TSLP. (A) The sequence given is a composite of three clones (see Mate-
rials and Methods). The signal peptide is in italics; amino acid number-
ing begins with the NH2 terminus of the mature protein (Tyr1). Poten-
tial sites of N-linked carbohydrate addition are underlined. Cysteines are
double underlined. Although there is no stretch of polyA at the 39 end
of our clones, it is likely that the AATAAA sequence at nucleotides
1111–1116 represents a polyadenylation signal, since the clone contain-
ing it was isolated from an oligo-dT–primed cDNA library. TSLP se-
quence data are available from EMBL/GenBank/DDBJ under accession
no. AF232937. (B) Schematic representation of cysteine residues and
potential glycosylation sites.675 Sims et al.
spretus. The Tslp gene lies between desmoglein 1 (Dsg1) on
the centromere-proximal side and Apc on the telomeric
side (Fig. 3). Given the close linkage between Tslp and Apc
in the mouse, the human homologue of Tslp most likely
maps to human chromosome 5q21–q22. Mouse mutations
mapping to this general vicinity (chromosome 18) include
spm (a sphingomyelinase deficiency) and ataxia (ax).
Protein Characterization. Recombinant TSLP expressed
in mammalian cells (CV-1/EBNA) was purified to near ho-
mogeneity using a four-step procedure. The final two steps,
gel filtration chromatography and RP-HPLC, partially re-
solved TSLP into a 23-kD major species and an 18-kD mi-
nor species as shown by SDS-PAGE. These estimations are
in good agreement with those of natural TSLP expressed by
Z210R.1 cells (24 and 20 kD), as determined by radioiodi-
nation of partially purified natural TSLP, binding to
NAG8/7 cells, and elution followed by SDS-PAGE (data
not shown). The molecular weight difference for the two
forms is probably due to differences in N-linked glycosyla-
tion, as N-glycanase treatment reduced their molecular
weights to z14,000 (data not shown), which is close to the
calculated molecular weight from the cDNA sequence
(13,967). Purified TSLP was analyzed by 30 cycles of NH2-
terminal sequence analysis. The sequence corresponded to
that shown in Fig. 1 A beginning at residue 20, tyrosine.
This is in agreement with the cleavage site predicted from
the cDNA sequence (27). Amino acids were not identified
on cycles 6 and 16, which are predicted to be cysteine resi-
dues, and cycle 7, which is predicted to be an asparagine
and an N-linked glycosylation site. Asparagine on cycle 2,
which is also predicted to be an N-linked glycosylation site,
Figure 2. Analysis of TSLP mRNA expression in various tissues. (A)
Northern analysis of indicated tissue or cell line polyA1 mRNA with an
antisense TSLP probe. (B) RT-PCR of TSLP mRNA expression in vari-
ous tissues: (a and b) TSLP RT-PCR reaction products from indicated
samples of cDNA amplified for 35 or 40 cycles, respectively; (c) normal-
ization of cDNA sample amount using HPRT PCR primers and an
HPRT competitor; (d) PCR of mock-transcribed samples. BM, bone
marrow; L. node, lymph node; Skel., skeletal.
Figure 3. Tslp maps in the proximal region of mouse chromosome 18.
Tslp was placed on mouse chromosome 18 by interspecific backcross
analysis. The segregation patterns of Tslp and flanking genes in 148 back-
cross animals that were typed for all loci shown at the top of the figure.
For individual pairs of loci, .148 animals were typed. Each column rep-
resents the chromosome identified in the backcross progeny that was in-
herited from the (C57BL/6J 3 M. spretus)F1 parent. The black boxes rep-
resent the presence of a C57BL/6J allele and the white boxes represent
the presence of the M. spretus allele. The number of offspring inheriting
each type of chromosome is listed at the bottom of each column. A partial
chromosome 18 linkage map showing the location of Tslp in relation to
linked genes is shown at the bottom of the figure. The number of recom-
binant animals is presented over the total number of animals typed to the
left of the chromosome map between each pair of loci. Recombination
frequencies expressed as genetic distance in cM (61 SE) The positions of
loci in human chromosomes, where known, are shown to the right. Ref-
erences for the human map positions of loci cited in this study can be ob-
tained from Genome Data Base (www.gdb.org), a computerized database
of human linkage information maintained by The William H. Welch
Medical Library of The Johns Hopkins University (Baltimore, MD).676 Murine TSLP
was detected, suggesting that it is not glycosylated. Analysis
by SDS-PAGE under reducing and nonreducing conditions
produced similar results, suggesting that TSLP is not dimer-
ized by an intermolecular disulfide bond (data not shown).
TSLP contains seven cysteine residues, which could po-
tentially form as many as three disulfide bonds. To identify
the disulfide bonding pattern, purified TSLP from CV-1/
EBNA cells was digested under native conditions with
trypsin and the resulting peptides were identified by pro-
tein sequencing. A single sequence was obtained for resi-
dues 14–28 indicating that cys-16 was not disulfide linked.
This result was confirmed by RP-HPLC/mass spectrome-
try of a TSLP tryptic digest which showed a mass of
1,765.96 compared with the expected mass of 1,766.07. A
single sequence was also obtained for residues 32–47,
which contains two cysteine residues. RP-HPLC/mass
spectrometry showed a mass of 1,851.76, which compares
favorably with the expected mass of 1,852.14 for this pep-
tide with an internal disulfide bond between cys-38 and
cys-44. Sequences corresponding to residues 1–13 and 73–
87 coeluted, suggesting that cys-6 and cys-79 are disulfide
linked. Similarly, sequences corresponding to residues 48–
65 and 88–111 coeluted, suggesting that cys-59 and cys-
102 are disulfide linked. Therefore, cysteine residues 6 and
79, 38 and 44, and 59 and 102 form three disulfide bonds,
whereas cysteine residue 16 is not disulfide linked.
TSLP Effects on Lymphoid Progenitors and Myeloid Colony-
forming Cells. Recombinant TSLP expressed transiently in
mammalian cells (CV-1/EBNA) or expressed in yeast (K.
lactis), and purified as described was tested for biological ac-
tivity in the NAG8/7 bioassay. A dose-dependent stimula-
tion of thymidine incorporation was observed with both
preparations of TSLP having comparable specific activity of
z20,000 U/mg protein (data not shown).
Pre-B cells have previously been shown to grow clonally
in semisolid medium when stimulated with IL-7 (21, 23).
We tested the ability of TSLP to support the clonal growth
of normal murine bone marrow cells under conditions that
are permissive for pre-B colony growth in agarose cultures.
Parallel cultures of normal murine bone marrow cells were
initiated in the presence of either IL-7 or TSLP at various
concentrations. Growth of colonies was observed in the
presence of either cytokine (data not shown). Colonies
were composed of 40 or more small mononuclear cells that
had the morphological appearance of resting lymphocytes.
Clone size was noticeably larger in the presence of IL-7
than TSLP, and the number of colonies at plateau concen-
trations of IL-7 was approximately twofold greater than the
number of colonies developing in the highest effective
concentration of TSLP (data not shown). Colony growth
in TSLP was strictly dose dependent, with half-maximal
colony formation stimulated by z2 ng/ml of purified K.
lactis or mammalian expressed TSLP (data not shown).
Treatment of murine bone marrow with anti-B220 plus
complement eliminated the growth of colonies in response
to IL-7 or TSLP, but had no effect on granulocyte and/or
macrophage colonies in response to GM-CSF, IL-3, CSF-1,
or G-CSF (data not shown). The addition of 20 ng/ml
of purified TSLP to cultures of whole bone marrow or
bone marrow depleted of B2201 cells (by either comple-
ment lysis or magnetic bead separation) and stimulated with
plateau concentrations of GM-CSF, IL-3, CSF-1, or G-CSF
had no effect on the number of myeloid colonies (data not
shown). Thus, TSLP stimulates B cell precursor growth but
has no demonstrable effect on myeloid committed precur-
sor cells in murine bone marrow.
Previous studies (6) had shown that cocultures of Z210R.1
stromal cells with fetal liver cells resulted in the develop-
ment of surface m1 cells. To ascertain that this activity was
indeed due to TSLP, cultures of B2201surface Ig (sIg)M2
bone marrow cells were established in methylcellulose in
the presence of TSLP. After 7 d of culture, cells were iso-
lated from harvested colonies, stained, and analyzed by
flow cytometry. These cells expressed B220, surface IgM,
and low levels of Mac-1, but were negative for expression
of Thy-1 (Fig. 4).
Since TSLP was cloned from a stromal cell line derived
from murine thymus, its ability to support thymocyte
growth was evaluated. TSLP was tested for growth-stimu-
lating activity on cultures of whole thymocytes or purified
adult CD42CD82 thymocytes both alone and with other
cytokines. TSLP failed to stimulate a proliferative response
either alone or in the presence of other cytokines in cul-
tures of whole adult thymocytes (data not shown). In cul-
tures of CD42CD82 thymocytes, TSLP had minimal pro-
liferative activity alone, but significant synergy was seen
when TSLP was combined with IL-1 (Table I). There was
no stimulatory activity of TSLP with other cytokines (IL-2,
IL-3, IL-4, or IL-7) in this type of assay (data not shown).
Previously, it has been shown that IL-7 stimulates signifi-
cant growth of thymocytes in submersion cultures of intact
day 14 fetal thymic lobes and that SCF (c-kit ligand) syner-
gizes with IL-7 in this culture system (24). The activity of
TSLP was assessed in this culture system, and it can be seen
in Table II that in contrast to IL-7, TSLP had minimal
Figure 4. Cell surface phenotype of bone marrow colonies grown in
TSLP. Whole bone marrow cells were cultured for 7 d in methylcellulose
plus TSLP (20 ng/ml). Colonies were plucked from the semisolid media,
pooled, and disrupted. Cells were stained with the appropriate reagents as
indicated and analyzed via flow cytometry.677 Sims et al.
growth-stimulating activity on its own and did not syner-
gize with SCF.
Effects of TSLP or IL-7 Administration on B Lymphopoiesis
In Vivo. Four distinct stages of adult murine B cell matu-
ration were defined by Hardy et al. through the use of mul-
tiparameter flow cytometry (28). In that study, one of the
earliest committed B cell precursors, the pre–pro-B cell was
defined by the expression of CD45R and CD43 (leukosia-
lin) on sIgM2 bone marrow cells. This cell is thought to
give rise to the pro-B cell that is defined by decreased ex-
pression of CD43 and increased expression of HSA. The
transition from pro-B cell to pre-B cell is determined by the
induction of expression of BP-1. To ascertain the effects of
TSLP administration in vivo, 7-d-old neonatal mice were
injected daily intraperitoneally with either TSLP or IL-7 for
10 d. The next day, spleen and bone marrow were har-
vested for assessment of pre-B cell subpopulations by flow
cytometry as described (28). The dosage and schedule of
cytokine administration were based on previous studies
done with IL-7 (Morrissey, P.J., unpublished observations).
The phenotypic composition of bone marrow pre-B cell
populations was determined by four-color flow cytometry.
Gates were set on the sIgM2sIgD2 bone marrow cells, and
this population was analyzed for expression of B220 and
BP-1. As can be seen in Fig. 5 A, mice treated with either
TSLP or IL-7 had a significantly greater percentage of
B2201BP-11 pre-B cells. This observation is consistent
with previous work that has shown that IL-7 induces BP-1
expression on pre-B cells and increases this population
when administered to mice (29, 30). Further phenotypic
analysis was performed to determine if other changes could
be observed in earlier populations of B cell precursors.
Table I. Synergistic Activity of TSLP on IL-1–induced 
CD42CD82 Thymocyte Proliferation
IL-1b
TSLP None 20 ng/ml
cpm
None 84 6,063
1/10 112 21,968
1/50 114 16,677
1/250 95 9,113
Control SN
1/10 120 7,037
1/50 105 7,443
1/250 61 6,981
The data are the average cpm of quadruplicate values. Cells were
cultured for 3 d. The SEM was ,5% of the mean for all values (data not
shown). TSLP and control SN were yeast culture supernatants. The data
are from a single experiment that has been performed three times with
similar results.
Table II. Cell Yield from Fetal Thymus Lobe
Submersion Cultures
Culture conditions Cell yield/well
31025
No cytokine 0.26
TSLP 0.51
IL-7 5.9
SCF 1.1
TSLP 1 SCF 2.6
IL-7 1 SCF 11.5
TSLP 1 IL-7 3.7
TSLP 1 IL-71 SCF 11.8
Whole day 14 fetal thymi were cultured as described (see Materials and
Methods) with the indicated cytokines. After 7 d of culture, the wells
were harvested and viable cell numbers were determined. The data are
from a single experiment that has been performed three times with
similar results.
Figure 5. Analysis of bone marrow pre-B cells from mice treated with
TSLP or IL-7. Neonatal C57BL/6 mice were injected with MSA, TSLP,
or IL-7 for 10 d as described above (see Materials and Methods). 1 d after
cessation of treatment, bone marrow was harvested, stained, and ana-
lyzed. (A) BP-1 and B220 expression on sIgM2sIgD2 bone marrow
cells. (B) CD43 (S7) and HSA (M1/69) expression of IgM2B2201 bone
marrow cells.678 Murine TSLP
Thus, CD43 and HSA expression were analyzed in the
sIgM2B2201 cell population. As can be seen in Fig. 5 B,
there was no appreciable difference in the expression of
CD43 or HSA in the B2201sIgM2 pre-B cells between
control, TSLP-, and IL-7–treated mice. In these cytokine-
treated mice, there was significant splenomegaly (twofold
over controls), which was due predominantly to an accu-
mulation of B2201sIgM1 B cells (data not shown). Again,
there was no significant difference in numbers or phenotype
of the splenic B cell population between IL-7– and TSLP-
treated mice. These results indicate that TSLP administra-
tion enhances B cell production and increases B cell num-
bers, and that there is no appreciable difference between
TSLP and IL-7 in the parameters examined in this study.
Discussion
The cloning of a novel murine gene that encodes a pro-
tein with lymphopoietic activity is described. The activity
was initially identified in a coculture system of an adherent
thymic stromal cell line with a medullary phenotype,
Z210R.1, and day 15 fetal liver (6). Interestingly, the non-
adherent lymphoid-like cells that grew in these cocultures
phenotypically resembled B cells. A clonal lymphoid line
(NAG8/7) was derived from long term cocultures, and this
line expresses B220, 6C3 (BP-1), and is surface m1, but k
chain negative. Importantly, NAG8/7 cells proliferated in
response to conditioned medium from the Z210R.1 cell
line and thus became the basis of a bioassay that allowed for
the preliminary characterization of the growth factor and
the eventual cloning of the cDNA encoding this activity.
The cDNA encoding the NAG8/7 growth activity was
cloned from a library made from the Z210R.1 cell line.
Based on the nucleotide sequence, the mature TSLP pro-
tein consists of 121 amino acids with 3 potential N-glyco-
sylation sites and 7 cysteine residues. Interestingly, IL-7 is a
129–amino acid protein with 2 N-linked glycosylation sites
and 7 cysteine residues. Comparison of both the nucleotide
and amino acid sequences, however, reveals no significant
degree of homology between TSLP and IL-7. Additionally,
TSLP maps to mouse chromosome 18, whereas IL-7 maps
to mouse chromosome 3.
Northern and RT-PCR analysis of mRNA prepared
from various tissues and cell lines revealed detectable ex-
pression of TSLP in spleen, thymus, kidney, lung, and
bone marrow of normal mice. Brain, liver, heart, ileum,
and skeletal muscle were negative. Variable expression of
TSLP was detected in lymph nodes by RT-PCR. IL-7 has
been shown to be expressed in spleen, thymus, and kidney,
but not liver, by Northern analysis. In addition, there is ev-
idence to suggest that IL-7 gene expression may be compli-
cated by the use of differential splicing and/or polyadenyla-
tion (3). No such evidence has been found to date from the
studies of gene expression of TSLP.
The biological activities of TSLP and IL-7 share interest-
ing commonalities. Friend et al. have shown that coculture
of day 15 fetal liver with the Z210R.1 cells resulted in the
generation of a significant proportion of cells that were sur-
face m1, although the appearance of significant numbers of
m1 cells was relatively later in the culture period (6). How-
ever, similar experiments performed with IL-7 or IXN/
2AB stromal cell lines also result in the growth of pre-B
cells that are uniquely surface m2. Thus, these findings sug-
gest that TSLP appears to support the ability of pre-B cells
to differentiate to a more mature stage than IL-7. Interest-
ingly, Ray et al. reported that B2201 day 15 fetal liver cells
grown in suspension culture for 4 d with TSLP were
B2201, but remained largely surface m2, similar in pheno-
type to those grown in IL-7 (31). However, there was an
equivalent proliferative response of these cells when subse-
quently stimulated with IL-7 and TSLP. Here we demon-
strate that the colonies that arose from B2201sIgM2 bone
marrow cells from adult mice grown in semisolid medium
with TSLP for 7 d were sIgM1. The reasons for these
somewhat discrepant results are not immediately clear, al-
though the culture systems, starting cell populations, and
concentrations of growth factors used are different. Thus,
the issue of the comparative activities of TSLP and IL-7 on
pre-B cells remains to be elucidated.
Ray et al. also reported that TSLP, similar to IL-7, was
not able to support the development of B2201 fetal liver
cells to the stage of becoming responsive to maturation to
IgM-secreting cells when cultured secondarily with LPS
and S17 stromal cells (31). In addition, neither IL-7 nor
TSLP can act as a comitogen for mature splenic B cells
stimulated with immobilized anti-Ig in vitro (Maliszewski,
C., Immunex Corp., personal communication). Thus, we
can conclude that IL-7 and TSLP are both able to support
B lymphopoiesis from early progenitor cells but that TSLP
may support B cell development to a more mature stage
than IL-7.
Since TSLP was cloned from a thymic-derived stromal
cell line, its effect on T lymphopoiesis was also studied in
vitro. TSLP had little effect on the proliferation of adult
CD42CD82 thymocytes in cell suspension culture either
alone or with IL-2 or IL-7, but did synergize with IL-1. In
lobe submersion culture using day 15 fetal thymus lobes,
the addition of IL-7 and IL-7 plus SCF dramatically in-
creased the cell yield per cultured thymic lobe (24). In this
system, TSLP had a minimal effect either alone or in com-
bination with SCF. Thus, at least in these culture systems,
TSLP does not appear to have potent growth-stimulating
abilities for CD42CD82 thymocytes.
It is interesting to consider the biological activity of TSLP
described here with the observations generated from the
study of cytokine and cytokine receptor gene knockout
mice. Although many cytokine or cytokine receptor genes
have been deleted, only mice with targeted disruptions of
the IL-7, IL-7R, or gc gene show profound T and B cell
lymphopenia (32–34). Interestingly, IL-7R2/2 mice have a
B cell maturational arrest at an earlier stage than IL-72/2
mice, and the lymphopenia in the IL-7R, IL-7, and gc
knockout mice is not absolute, suggesting that another
ligand that may utilize the IL-7R but not gc would be able
to support a low level of lymphopoiesis. Park et al. (7) de-
scribe the cloning of a unique receptor for TSLP and pro-679 Sims et al.
pose the use of the IL-7R, but not gc, by TSLP. Mice in-
jected with TSLP have the identical phenotype as mice
injected with IL-7, showing enhanced B lymphopoiesis and
increased B cell numbers in the spleen (30). However, if
TSLP were purely a “functionally redundant” cytokine, it
might be predicted that there would be a minimal effect of
deleting the IL-7 gene. Since there is severe lymphopenia in
these animals, it must be concluded that IL-7 plays a pre-
dominant role in lymphopoiesis. Interestingly, a preliminary
report of TSLP transgenic mice where the transgene is
driven by the proximal lck promoter describes the develop-
ment of profound pathology and the transgenic line with
high copy number surviving only to 3–4 wk of age (35). At
lower transgene copy number, extensive pathology consis-
tent with chronic inflammation and autoimmunity develops.
We had invested a substantial amount of effort in at-
tempts to clone a human homologue of TSLP with no suc-
cess (Sims, J.E., and K. Garka, data not shown). Reduced
stringency hybridization of a murine TSLP riboprobe to
filters containing human mRNA showed a hybridizing
species of a size similar to that of murine TSLP mRNA, yet
we were unable to clone a corresponding cDNA from sev-
eral libraries derived from the same mRNA sources. Ge-
nomic Southern blots of human DNA digested with several
different restriction enzymes showed a single band that hy-
bridized to the murine TSLP probe. We isolated genomic
clones that appeared to correspond to this hybridizing
band, but by sequence they clearly did not represent hu-
man TSLP. More recently, however, we have identified a
human expressed sequence tag that resembles murine
TSLP. This impression is confirmed by isolation of full-
length cDNA clones corresponding to the same mRNA
from which the expressed sequence tag was derived (Sims,
J.E., R.F. DuBose, and S.D. Lyman, unpublished data). It
remains to be seen whether the biological activities of the
mouse and human TSLP are less divergent than their se-
quences.
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